The effect of injectable scopolamine in patients with major depressive disorders

The augmentation effect of injectable scopolamine in the improvement of clinical symptoms of patients with major depressive disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231017059749N1

Enrollment

Registered

2023-10-21

Start date

2023-10-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Major depressive disorder, single episode

Interventions

Intervention 1: Intervention group: In addition to standard treatment (SSRI), patients will receive 0.5 mg scopolamine intramuscularly daily for three days. Intervention 2: Intervention group: Patient

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients with major depressive disorder Age 18-55 years Minimum severity of depression based on Hamilton Depression Scale should be higher or equal to 20.

Exclusion criteria

Exclusion criteria: The existence of psychotic disorder, delirium and bipolar disorderPregnancy or breastfeeding Taking psychedelic drugs, antidepressants in the last month ECT in the last two months History of cardiovascular disease Hypothyroidism

Design outcomes

Primary

Measure	Time frame
Hamilton depression scale. Timepoint: The beginning of the study, the fourth day, the seventh day, the fourteenth day, the twenty-eighth day. Method of measurement: Hamilton questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Alireza Kmali

Arak University of Medical Sciences

alikamaliir@yahoo.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026